Cardiac Glycosides Decrease Prostate Specific Antigen Expression by Down-Regulation of Prostate Derived Ets Factor
- 1 November 2010
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 184 (5) , 2158-2164
Abstract
While cardiac glycosides are the mainstay of congestive heart failure treatment, early studies showed that pharmacological doses of cardiac glycosides inhibited prostate cancer cell line proliferation. We evaluated the mechanisms of cardiac glycosides, including digoxin, digitoxin and ouabain (Sigma®), on prostate specific antigen gene expression in vitro. We cultured LNCaP cells (ATCC®) and used them to determine the effect of cardiac glycosides on prostate derived Ets factor and prostate specific antigen expression. We determined prostate derived Ets factor and prostate specific antigen expression by reverse transcription-polymerase chain reaction, immunoblot, transient gene expression assay or enzyme-linked immunosorbent assay. Noncytotoxic doses (100 nM) of cardiac glycosides for 24 hours inhibited prostate specific antigen secretion by LNCaP cells. Reverse transcriptase-polymerase chain reaction and immunoblot revealed that cardiac glycosides significantly down-regulated prostate specific antigen and prostate derived Ets factor expression. Transient gene expression assays showed that prostate derived Ets factor over expression enhanced prostate specific antigen promoter activity. However, prostate specific antigen and prostate derived Ets factor gene promoter activity was attenuated when LNCaP cells were treated with 100 nM cardiac glycosides. When LNCaP cells were treated with 25 nM digitoxin or digoxin for 60 hours, prostate specific antigen secretion decreased by 30%. Results suggest that cardiac glycoside inhibition of prostate specific antigen gene expression may be caused by the down-regulation of prostate derived Ets factor gene expression. When cells were chronically treated with digoxin or digitoxin at concentrations close to or at therapeutic plasma levels, prostate specific antigen secretion decreased. This phenomenon merits further study to determine whether it occurs in men on cardiac glycoside therapy.Keywords
This publication has 23 references indexed in Scilit:
- Curcumin Blocks the Activation of Androgen and Interlukin‐6 on Prostate‐Specific Antigen Expression in Human Prostatic Carcinoma CellsJournal of Andrology, 2008
- Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progressionHuman Pathology, 2007
- Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growthAmerican Journal of Physiology-Cell Physiology, 2007
- Phytoestrogens from Belamcanda chinensis regulate the expression of steroid receptors and related cofactors in LNCaP prostate cancer cellsBJU International, 2007
- THE PROSTATE SPECIFIC ANTIGEN ERA IN THE UNITED STATES IS OVER FOR PROSTATE CANCER: WHAT HAPPENED IN THE LAST 20 YEARS?Journal of Urology, 2004
- Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cellsBiochemical Pharmacology, 2004
- Endogenous cardiac glycosides, a new class of steroid hormonesEuropean Journal of Biochemistry, 2002
- Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and stagingUrology, 2000
- PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene ExpressionJournal of Biological Chemistry, 2000
- EFFECTS OF OUABAIN ON TENSION RESPONSE AND [ 3 H]NORADRENALINE RELEASE IN HUMAN PROSTATEJournal of Urology, 2000